Mumbai:
Shares of Sun Pharmaceutical Industries surged over 8 per cent on Monday, April 27, 2026, after the firm announced that it will acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of USD 11.75 billion. The stock reacted positively to this development, as it is expected to be one of the largest acquisitions by Indian firms overseas.
Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the US and Canada, in 2021.
